Ovid Therapeutics Inc.
OVID · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $566 | $392 | $1,503 | $208,383 |
| % Growth | 44.4% | -73.9% | -99.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $566 | $392 | $1,503 | $208,383 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $36,767 | $28,588 | $24,618 | $46,940 |
| G&A Expenses | $25,683 | $29,585 | $32,432 | $37,233 |
| SG&A Expenses | $25,683 | $29,585 | $32,432 | $37,233 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1,500 | $1 | $1 |
| Operating Expenses | $62,451 | $59,673 | $57,051 | $84,174 |
| Operating Income | -$61,885 | -$59,281 | -$55,548 | $124,209 |
| % Margin | -10,933.7% | -15,122.7% | -3,696.4% | 59.6% |
| Other Income/Exp. Net | $35,452 | $6,942 | $1,379 | -$46 |
| Pre-Tax Income | -$26,433 | -$52,339 | -$54,169 | $124,163 |
| Tax Expense | $0 | $0 | $0 | $1,329 |
| Net Income | -$26,433 | -$52,339 | -$54,169 | $122,835 |
| % Margin | -4,670.1% | -13,351.8% | -3,604.7% | 58.9% |
| EPS | -0.37 | -0.74 | -0.77 | 1.78 |
| % Growth | 50% | 3.9% | -143.3% | – |
| EPS Diluted | -0.37 | -0.74 | -0.77 | 1.76 |
| Weighted Avg Shares Out | 70,905 | 70,581 | 70,425 | 67,479 |
| Weighted Avg Shares Out Dil | 70,905 | 70,581 | 70,425 | 68,068 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,900 | $4,900 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $613 | $568 | $1,382 | $237 |
| EBITDA | -$57,772 | -$57,013 | -$54,166 | $124,447 |
| % Margin | -10,207.1% | -14,544.1% | -3,604.5% | 59.7% |